Jun Xu

Jun Xu

Auto-generated profile, based on publicly available information

Jun Xu

Baylor College of Medicine 7 Advanced Cell Engineering and 3D Models Core, Department of Biochemistry and Molecular Biology Houston, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
AHAnh Minh Tran Huynh
Anh Minh Tran Huynh
JLJonathan T. Lei
Jonathan T. Lei
RBRachel Brough
Rachel Brough
CSChristina Sallas
Christina Sallas
JXJun Xu
Jun Xu
MAMeenakshi Anurag
Meenakshi Anurag
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.